期刊文献+

美托洛尔与毛花苷快速控制心房颤动心室率的比较 被引量:1

Fast effect of intravenous metoprolol on the treatment of rapid ventricular rate in patients with atrial fibrillation
下载PDF
导出
摘要 目的:比较静脉应用美托洛尔与毛花(洋地黄)苷快速控制心房颤动患者心室率的疗效和安全性。方法:68例快速心房颤动患者(心室率≥120次/min),随机分为美托洛尔组、毛花苷组各34例。美托洛尔组首次剂量给予5mg缓慢静注,观察15min,若心室率>100次/min或下降<20%,则追加5mg,最多给药10mg,若血压<90/60mmHg,则停止试验;毛花苷组首次剂量给予毛花苷0.4mg或0.2mg缓慢静注,若心室率>100次/min或下降<20%,则追加0.2mg。观察两组用药后10min、30min、60min、90min和120min心率,血压及临床表现;同时记录用药后药物起效时间及不良反应。结果:两组患者用药后2h内的心室率与用药前比较均明显降低(P<0.05),用药2h后美托洛尔组心室率下降幅度大于毛花苷组(P<0.05);美托洛尔、毛花苷组平均起效时间分别为(12.4±6.7)min和(41.6±11.2)min,两者差异有显著性(P<0.01);美托洛尔、毛花苷组总有效率分别为88%和76%无显著性差异(P>0.05);两组不良反应发生率均为12%。结论:静脉应用美托洛尔控制快速心房颤动患者心室率的短时疗效显著,患者安全性好。 Objective: To evaluate the short-term efficacy of intravenous metoprolol and lanatoside on treatment of rapid ventrieular rate in patients with atrial fibrillation (Af). Methods: Sixty-eight patients with Af (ventrieular rate ≥120 beats/ minute) were randomly divided into two groups. The two groups were intravenously administered metoprolol or lanatoside respectively. Heart rate and the mean response time were measured after the treatment. Adverse effects were recorded. Results: Ventricular rate significantly decreased after treatment in two groups, but the venrricular rate was lower in the motoprolol group than that of the lanatoside group (P〈0.05). The mean response time was (12.4 ±6, 7) min and (41.6±11.2) min in metoprolol and lanatoside groups respectively. No significantly difference of total effective rate in controlling rapid Af were found between two groups (88% in metoprolol group versus 76% in lanatoside group). Conclusion: Intravenous metoprolol is efficient, rapid and safe in the treatment of rapid ventricular rate in patients with Af.
出处 《心血管康复医学杂志》 CAS 2008年第5期487-489,共3页 Chinese Journal of Cardiovascular Rehabilitation Medicine
关键词 美托洛尔 毛花洋地黄甙 心房颤动 心率 Metoprolol Lanatoside Atrial fibrillation Heart rate
  • 相关文献

参考文献8

  • 1Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis [ J]. Lancet, 2006, 368 ( 9536 ) : 679 - 686.
  • 2郭继鸿.β受体阻滞剂在心律失常治疗中的应用[J].中国心脏起搏与心电生理杂志,2007,21(1):4-6. 被引量:49
  • 3Chung MK, Shemanski L, Sherman DG, et al. Functional status in rate-versus rhythm-control strategies for atrial fibrillation : results of the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) functional status substudy [J]. J Am Coll Cardiol, 2005, 46 (10): 1891-1899.
  • 4Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation) : developed in collaboration with the European heart rhythm association and the heart rhythm society [J]. Circulation, 2006, 114 (7): 257-354.
  • 5戚文航.中国部分地区心房颤动住院病例回顾性调查[J].中华心血管病杂志,2003,31(12):913-916. 被引量:380
  • 6Demircan C, Cikriklar HI, Engindeniz Z, et al. Comparison of the effectiveness of intravenous diltiazem and metoprolol in the management of rapid ventricular rate in atrial fibrillation [J]. Emerg Med J, 2005, 22 (6): 411-414.
  • 7Hersi A, Wyse DG. Management of atrial fibrillation [J]. Curr Probl Cardiol, 2005, 30 (4): 175-233.
  • 8林斌,章耀,戴海岳.静脉注射美托洛尔、地尔硫卓治疗快速心房纤颤的临床疗效观察[J].心血管康复医学杂志,2007,16(1):69-71. 被引量:6

二级参考文献15

  • 1王琼.地尔硫(艹卓)在冠状动脉搭桥术后应用的疗效分析[J].心血管康复医学杂志,2005,14(1):58-58. 被引量:6
  • 2郭继鸿.β受体阻滞剂应当成为快速心律失常治疗的基础用药[J].中国心脏起搏与心电生理杂志,2005,19(5):331-334. 被引量:80
  • 3郑强,韩峰,韩新飞,臧彬.美托洛尔注射液治疗快速心房纤颤临床疗效观察[J].实用药物与临床,2006,9(2):90-92. 被引量:7
  • 4向小平 胡大一 崔亮.静脉注射地尔硫卓,美托洛尔和毛花甙C控制快速心房纤颤心室率的疗效和安全性比较[J].中华心血管病杂志,1995,23:11-13.
  • 5Demircam C,Cikkriklar HI,Engindeniz Z,et al.Comparison of the effectiveness of intravenous diltiazem and metoprololl in the management of rapid ventricular rate in atrial fibrillation[J].Emerg Med J,2005,22(6):411-414.
  • 6Dia VC,Weir ST,Ellenbagen KA.Phamacokinetic and pharmacodynanics of intravenous diltiazem in patients with atrial fibrillation or atrial flutter[J].Circulation,1992,86:1421-1428.
  • 7Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a muhidrug regimen in the developing world: a cost-effectiveness analysis[J]. Lancet, 2006,19,368(9536) :679
  • 8Lanza CA, Fox K, Crea F. Heart rate: a risk factor for cardiac diseases and outcomes? Pathophysiology of cardiac diseases and the potential role of heart rate slowing[ J ]. Adv Cardiol,2006,43:1
  • 9Siddiqui A, Kowey PR. Sudden death secondary to cardiac arrhythmias: mechanisms and treatment strategies[ J]. Curr Opin Cardiol,2006,21(5) :517
  • 10Viitasalo M, Oikarinen L, Swan H, et al. Effects of beta-blocker therapy on ventricular repolarization documented by 24 h electrocardiography in patients with type 1 long-QT syndrome[J]. J Am Coll Cardiol,2006,48 (4) :747

共引文献430

同被引文献9

  • 1Linde C. Quality of life in pacemaker patients. In SS Barold, J Mugica (ed): Recent advance in cardiac pacing: goals for the 21st century [M]. Armonk NY, Futura Publishing Company, 1998, 433-44.
  • 2Wood MA, Brown-Mahoney C, Kay GN, et al. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis [J]. Circulation, 2000, 101 (10): 1138-1144.
  • 3Kay GN, Ellenbogen KA, Giudici M, et al. The ablate and pace trial: a prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation. APT Investigators [J]. J Interv Card Electrophysiol, 1998, 2 (2): 121-135.
  • 4Brignole M, Menozzi C, Gianfranchi L, et al. Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation: a randomized, controlled study [J]. Circulation, 1998, 98 (10): 953-960.
  • 5Fananapazir L, Epstein ND, Curiel RV, et al. Long-term results of dual-chamber pacing in obstructive hypertrophic cardiomyopathy [J]. Circulation, 1994, 90: 2731-2742.
  • 6Prinzen FW, Cheriex EC, Arts T, et al. Changes in left ventricular diastolic wall thickness induced by chronic asynchronous electrical activation [J]. J Mol Cell Cardiol, 1992, 24 (suppl Ⅴ) : S50.
  • 7Reneman RS, Prinzen FW, Cheriex EC, et al. Asymmetrical changes in left ventricular diastolic wall thiekness induced by chronic asynchronous electrical activation in man and dogs [J]. FASEBJ, 1993, 7: A752.
  • 8Wyse DG, Waldo AL, DiMarco JP, et al. Atrial fibrillation follow-up investigation of rhythm management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation [J]. N Engl J Med, 2002, 347 (23): 1825-1833.
  • 9彭学军,朱灿,张晓莉,彭仙凤.静脉注射不同剂量盐酸地尔硫卓治疗快室率心房纤颤的观察[J].心血管康复医学杂志,2007,16(6):587-588. 被引量:1

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部